Skip to main content

Gene therapy reverses muscular dystrophy symptoms in dogs

As difficult as it is when our beloved pet dogs get old, it’s a whole lot worse if their decline is the result of a horrible disease like Duchenne muscular dystrophy, a genetic disorder characterized by progressive muscle degeneration and weakness. Fortunately, a team of gene-editing researchers from France and the U.K. have been working to develop gene therapy as an answer — and it’s one that could help humans, too.

Their solution involves using gene therapy to restore muscle strength and stabilize clinical symptoms. This is achieved by way of a shortened version of the dystrophin gene, containing just 4,000 base pairs, which is combined with a viral vector and injected into patients.

Recommended Videos

“Duchenne muscular dystrophy is a debilitating muscle-wasting disease affecting young boys and male animals, which is caused by inheritance of a damaged gene,” George Dickson, professor of molecular cell biology at University of London, told Digital Trends. “There is currently no very effective cure. Our work has involved producing a healthy functioning copy of the damaged gene in the lab, and then using a harmless virus to carry the gene into the affected muscles, a so-called gene therapy.”

 

The gene treatment has so far been tested on twelve golden retrievers affected by Duchenne muscular dystrophy. After a single dose, the dogs’ dystrophin production — the protein responsible for maintaining the integrity and strength of muscles — returned to its normal levels. Best of all, the trial was carried out a few years back, and all signs point to this being a lasting treatment. A paper describing the work was recently published in the journal Nature Communications.

“We now have treated a number of dogs affected by this condition with a single round of gene therapy,” Dickson continued. “At the correct dose, the results have been very encouraging with dogs looking very active and healthy over 3 years after the treatment. The treatment involves a simple intravenous infusion, a one-off treatment, and we have been very pleased and quite surprised at how effective the gene therapy has been given that muscle is a major tissue spread all over the body.”

Next up, the researchers hope to extrapolate the findings to human children, since they they are roughly the same weight and display similar clinical symptoms to canines.

“The goal is to expand this gene therapy treatment into human patients, boys suffering from the Duchenne muscular dystrophy disease,” Dickson said. “We have to scale up production of the gene therapy medicine for human use, complete more safety tests, and then embark on recruiting patients into full-scale clinical trials.”

Should all go according to plan, it’ll be another reminder of why gene therapy is the future of medicine as we know it.

Luke Dormehl
I'm a UK-based tech writer covering Cool Tech at Digital Trends. I've also written for Fast Company, Wired, the Guardian…
Sebastian Stan lays out Bucky’s future after Thunderbolts
Sebastian Stan in Thunderbolts.

There are some spoilers ahead for the ending of Marvel's Thunderbolts. Stop reading now if you don't want to be spoiled.

Earlier this year, Captain America: Brave New World briefly introduced a new direction for James "Bucky" Barnes, a character Sebastian Stan has been playing since 2011 in Captain America: The First Avenger. In Brave New World, the former Winter Soldier apparently retired from being a reformed hero and went into politics by running for Congress. Thunderbolts reveals that Bucky won his election to the House of Representatives. But his stay in Congress was short.

Read more
Jeep Compass EV breaks cover—but will it come to the U.S.?
jeep compass ev us newjeepcompassfirsteditionhawaii  4

Jeep just pulled the wraps off the all-new Compass EV, and while it’s an exciting leap into the electric future, there's a catch—it might not make it to the U.S. anytime soon.
This is a brand new electric version of the Jeep Compass, and being built on Stellantis' STLA platform—the same architecture underpinning models like the Peugeot E-3008 and E-5008—it looks much slicker and packs a lot more inside than previous versions of the Compass.
Let’s start with what’s cool: the new Compass EV is packing up to 404 miles of range on a single charge, a 74 kWh battery, and fast-charging that gets you from 20% to 80% in about 30 minutes. Not bad for a compact SUV with Jeep's badge on the nose.
There are two versions: a front-wheel-drive model with 213 horsepower and a beefier all-wheel-drive version with 375 horsepower. That AWD setup isn’t just for looks—it can handle 20% inclines even without front traction, and comes with extra ground clearance and better off-road angles. In short, it’s still a Jeep.
The design's been refreshed too, and inside you’ll find the kind of tech and comfort you’d expect in a modern EV—sleek, smart, and ready for both city streets and dirt trails.
But here’s the thing: even though production starts soon in Italy, Jeep hasn’t said whether the Compass EV is coming to America. And the signs aren’t promising.
Plans to build it in Canada were recently put on hold, with production now delayed until at least early 2026. Some of that might have to do with possible U.S. tariffs on Canadian and Mexican vehicles—adding a layer of uncertainty to the whole rollout.
According to Kelley Blue Book, a Stellantis spokesperson confirmed that the company has “temporarily paused work on the next-generation Jeep Compass, including activities at” the Canadian plant that was originally meant to build the model. They added that Stellantis is “reassessing its product strategy in North America” to better match customer needs and demand for different powertrain options.
So while Europe and other markets are gearing up to get the Compass EV soon, American drivers might be left waiting—or miss out entirely.
That’s a shame, because on paper, this electric Jeep hits a lot of sweet spots. Let’s just hope it finds a way over here.

Read more
Charlie Cox singles out his least favorite Daredevil: Born Again episode
Charlie Cox in Daredevil: Born Again.

Daredevil: Born Again season 1 was largely reconceived after the 2023 actor and writer strikes. Dario Scardapane -- a veteran of The Punisher series on Netflix -- was brought in to be the new showrunner and he made a lot of changes to the series that were well-received. However, there's one episode that Scardapane didn't really change at all, and it happens to be the least favorite episode of Daredevil: Born Again's leading man, Charlie Cox.

During an appearance on The Playlist, Cox noted that he wasn't very fond of the season's fifth episode, "With Interest," which was a largely standalone episode that featured his character, Matt Murdock, in a bank during a hostage crisis.

Read more